178 related articles for article (PubMed ID: 19085383)
1. Identification of a novel vascular endothelial growth factor receptor 2 inhibitor and its effect for choroidal neovascularization in vivo.
Takahashi H; Tamaki Y; Ishii N; Oikawa N; Mizuguchi E; Francis JH; Inoue Y; Iriyama A; Obata R; Yanagi Y
Curr Eye Res; 2008 Nov; 33(11):1002-10. PubMed ID: 19085383
[TBL] [Abstract][Full Text] [Related]
2. Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor.
Takeda A; Hata Y; Shiose S; Sassa Y; Honda M; Fujisawa K; Sakamoto T; Ishibashi T
Graefes Arch Clin Exp Ophthalmol; 2003 Sep; 241(9):765-72. PubMed ID: 12937991
[TBL] [Abstract][Full Text] [Related]
3. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
Kim KL; Suh W
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic effect of ALS-L1023, an extract of Melissa officinalis L., on experimental choroidal neovascularization in mice.
Roh YJ; Jee D; Rho CR; Cho WK; Kang S
Clin Exp Ophthalmol; 2016; 44(1):43-51. PubMed ID: 26221970
[TBL] [Abstract][Full Text] [Related]
5. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
6. A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo.
Takahashi H; Obata R; Tamaki Y
J Ocul Pharmacol Ther; 2006 Aug; 22(4):213-8. PubMed ID: 16910860
[TBL] [Abstract][Full Text] [Related]
7. Semaphorin 3A blocks the formation of pathologic choroidal neovascularization induced by transforming growth factor beta.
Bai Y; Liang S; Yu W; Zhao M; Huang L; Zhao M; Li X
Mol Vis; 2014; 20():1258-70. PubMed ID: 25352735
[TBL] [Abstract][Full Text] [Related]
8. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice.
Kang S; Roh YJ; Kim IB
Exp Eye Res; 2013 Jul; 112():125-33. PubMed ID: 23701975
[TBL] [Abstract][Full Text] [Related]
10. Effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of choroidal neovascularization.
Kang S; Park KC; Yang KJ; Choi HS; Kim SH; Roh YJ
Clin Exp Ophthalmol; 2013; 41(1):63-72. PubMed ID: 22594647
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA.
Gu L; Chen H; Tuo J; Gao X; Chen L
Exp Eye Res; 2010 Sep; 91(3):433-9. PubMed ID: 20599960
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor.
Kinose F; Roscilli G; Lamartina S; Anderson KD; Bonelli F; Spence SG; Ciliberto G; Vogt TF; Holder DJ; Toniatti C; Thut CJ
Mol Vis; 2005 May; 11():366-73. PubMed ID: 15951738
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the potential utility of a linomide analogue for treatment of choroidal neovascularization.
Abdel-Rahman MH; Yang Y; Salem MM; Meadows S; Massengill JB; Li PK; Davidorf FH
Exp Eye Res; 2010 Dec; 91(6):837-43. PubMed ID: 21055400
[TBL] [Abstract][Full Text] [Related]
14. The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo.
Wang W; Wang F; Lu F; Xu S; Hu W; Huang J; Gu Q; Sun X
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7213-20. PubMed ID: 21813636
[TBL] [Abstract][Full Text] [Related]
15. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser-induced CNV mouse model of neovascular AMD.
Wei X; Zhang T; Yao Y; Zeng S; Li M; Xiang H; Zhao C; Cao G; Li M; Wan R; Yang P; Yang J
Exp Eye Res; 2018 Mar; 168():2-11. PubMed ID: 29284110
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor.
Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Nov; 86 Thesis 4():42-9. PubMed ID: 19032681
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase.
Kami J; Muranaka K; Yanagi Y; Obata R; Tamaki Y; Shibuya M
Jpn J Ophthalmol; 2008; 52(2):91-98. PubMed ID: 18626731
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin.
Izumi-Nagai K; Nagai N; Ohgami K; Satofuka S; Ozawa Y; Tsubota K; Ohno S; Oike Y; Ishida S
Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1679-85. PubMed ID: 18385091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
